E Squared Capital Management

Biotech believes data will support approval as first disease-modifying therapy for non-advanced systemic mastocytosis

As more pharmas buy into phenotypic screening for novel target and drug discovery

Buysiders view 2021 as a window of opportunity for investing in targeted cancer drugs

Generalist surge into biotech likely to remain until economy recovers

Biotech likely to be top pick again in 3Q20, with a COVID-19 vaccine and politics the wild cards

Roller-coaster ride for Alzheimer’s therapy continues as investors reassess its chances for success submission.

Dealmaking has yet to slow down, and investors differ on when or if that will happen

Neurology is back, as buysiders home in on 2020 opportunities

An appetite for risk has plenty of investors considering biotech again in 2020. What elections?

Five 4Q takeouts above $1B in upfront value, data readouts buoy biotech indexes in 2019